Ceta-Plus

Quick links to important sections

Ceta-Plus

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ceta-Plus

Quick Facts

Property Description
Active Ingredients Hydrocodone Bitartrate, Acetaminophen (APAP)
Form Tablet (Oral dosage form)
Pharmacological Class Opioid/Non-opioid Combination Analgesic
Common Use Relief of moderate to severe pain
Origin Synthetic/Semi-synthetic

What Type of Medicine is Ceta-Plus?

Ceta-Plus is a potent, prescription-only medicine that is classified as a combination analgesic, specifically designed for managing pain. It is a synthetic product, created by chemical synthesis rather than direct extraction from natural sources. This formulation is structured as an opioid/non-opioid combination drug, distinguishing its identity as a dual-component treatment. Hydrocodone Bitartrate, the opioid component, is formally categorized as a semi-synthetic opioid derivative. This type of formulation is clinically recognized for providing effective relief in settings where simpler pain medications are insufficient.

Composition and Form: What is Ceta-Plus Made Of?

Ceta-Plus is a definitive combination product that contains two distinct active ingredients: Hydrocodone Bitartrate and Acetaminophen (Paracetamol). The standard pharmaceutical preparation of Ceta-Plus is an oral dosage form, specifically a solid tablet, intended for oral administration. The combination of these two agents is a distinguishing characteristic, found in common analogues such as Vicodin and Norco. Acetaminophen is classified as a widely used non-opioid analgesic and antipyretic agent.

What is the General Purpose of Ceta-Plus?

The general purpose of Ceta-Plus is to provide effective, centralized relief for moderate to severe pain, which often includes acute pain following medical or dental procedures. Its efficacy stems from a synergistic effect, meaning the two active ingredients work together to achieve greater pain relief than either could deliver independently. The combination of an opioid with Acetaminophen is recognized to enhance the overall analgesic effect. This means the medication helps provide stronger and more complete pain management when non-opioid options are inadequate for the level of discomfort experienced by the patient.

Regulatory References

  1. NIH StatPearls: Hydrocodone
  2. MedlinePlus Drug Information: Acetaminophen

What side effects are possible with Ceta-Plus?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics for Ceta-Plus (Hydrocodone Bitartrate and Acetaminophen), based strictly on governmental regulatory documents.

Most Frequently Reported Adverse Reactions

The most frequently reported adverse effects, particularly in ambulatory patients, are primarily related to the Central Nervous System. These include light-headedness, dizziness, sedation, nausea, and vomiting.

System-Organ Class Example Effects Listed in Regulatory Documents
Central Nervous System Drowsiness, mental clouding, lethargy, anxiety, psychic dependence.
Gastrointestinal System Constipation.
Genitourinary System Urinary retention, ureteral spasm.

Serious Adverse Reactions

The official prescribing information highlights risks that may be serious or life-threatening:

  • Life-threatening respiratory depression: A serious, dose-related risk associated with the Hydrocodone component.
  • Hepatotoxicity: The Acetaminophen component carries a risk of acute liver failure, often noted in Boxed Warnings, especially with high daily doses.
  • Neonatal Opioid Withdrawal Syndrome: A documented risk for newborns following prolonged use during pregnancy.

Safety Constraints and Special Populations

Ceta-Plus is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction (such as paralytic ileus), or known hypersensitivity to either active ingredient.

Safety notes for specific populations include:

  • Older Adults: May experience confusion and over-sedation; caution is advised due to potential for decreased renal function.
  • Renal/Hepatic Impairment: Caution is noted, as these conditions may increase the risk of toxic reactions due to slower clearance of the medication.

Repeated administration carries the potential for the development of physical dependence and tolerance.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official overdose profile for Ceta-Plus (Hydrocodone Bitartrate and Acetaminophen) is defined by the severe toxicities of its two active ingredients, which can be life-threatening and require immediate emergency response as mandated by government regulators.

Required Emergency Action

Seek immediate medical help right away for any suspected overdose, even if no obvious symptoms are present. Contact emergency services or a Poison Control Center immediately.

Primary Toxicity Risk Severe Outcome Documented
Opioid Component (Hydrocodone) Severe respiratory depression, cardiac arrest, circulatory collapse, coma.
Non-Opioid Component (Acetaminophen) Acute liver failure (hepatotoxicity), liver transplant, death.

Documented Overdose Manifestations

Overdose manifestations that regulators describe include symptoms from both drug components. Signs of severe opioid toxicity include slow and shallow breathing, cyanosis, extreme somnolence, pinpoint pupils, and hypotension. Symptoms of Acetaminophen toxicity may initially involve non-specific signs like nausea, vomiting, and diaphoresis.

Antidotes and Management

Regulatory documents specify distinct antidotes for management: Naloxone is required to reverse opioid-induced respiratory depression, and N-acetylcysteine is necessary to treat Acetaminophen toxicity. Management requires continuous surveillance, monitoring of vital signs, and reestablishment of adequate respiratory exchange.

Therapeutic Uses of Ceta-Plus

What Ceta-Plus Treats: Main Uses and Benefits

The primary purpose of Ceta-Plus (Hydrocodone Bitartrate and Acetaminophen) is to provide supportive symptom management in clinical settings marked by heightened patient distress, offering relief across key domains where symptoms become difficult to tolerate.

This medication is applied in addressing severe pain and, in certain formulations, is commonly used to help with cough. This combination is relevant in contexts marked by increased discomfort or tension, specifically where pain is categorized as moderate to severe and is commonly used when short-term symptomatic assistance is needed.

Relief of Key Symptom Clusters

This medication is generally used to manage intense physical discomfort, elevated body temperature (fever), and a persistent cough. These indications cover conditions characterized by periods of heightened symptoms, such as pain following surgical or dental procedures, discomfort from trauma, or in settings requiring ongoing support for chronic pain. The formulation is applied across domains where additional symptomatic support is needed.

“The combination is relevant for easing challenging symptoms and contributes to improved comfort.”

Quick Fact: Relief for Significant Discomfort

Symptom Severity Clinical Contexts Patient Benefit
Moderate to Severe Pain Acute, Postoperative, Trauma Supports the patient by easing distress
Concurrent Fever Symptom clusters with pain Contributes to improved comfort

This support helps maintain a sense of well-being when symptoms are more noticeable, assisting with pain management during episodes where the patient experiences heightened discomfort.

Regulatory References

  1. Hydrocodone and Acetaminophen MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Ceta-Plus?

Official regulatory documentation defines eligibility for Ceta-Plus (Hydrocodone Bitartrate and Acetaminophen) through a series of restrictions and mandatory contraindications.

Absolute Contraindications

The medicine is contraindicated in patients with known hypersensitivity to hydrocodone or acetaminophen. It must not be used by those with significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, or known or suspected gastrointestinal obstruction, including paralytic ileus.

Age and Organ Function Restrictions

The safety and effectiveness in pediatric patients have not been established for the tablet formulation. Elderly or debilitated patients must use the medicine with caution and require close observation. Use is restricted in patients with severe hepatic (liver) impairment or severe renal (kidney) impairment.

Pregnancy and Clinical Status

Ceta-Plus is classified as Pregnancy Category C. Use during pregnancy is only permitted if the potential benefit justifies the potential risk to the fetus, with prolonged use carrying the risk of Neonatal Opioid Withdrawal Syndrome (NOWS). During lactation, a decision must be made to discontinue nursing or discontinue the drug, as the excretion of hydrocodone is not definitively known. Caution is also required for those with a head injury or history of substance abuse.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Critical Pharmacodynamic Interactions

Central Nervous System (CNS) Depressants:

Concomitant use with other CNS depressants, including alcohol (ethanol), benzodiazepines (e.g., alprazolam), other opioids (narcotic analgesics), and certain sleep aids or muscle relaxants, carries a risk of potentially fatal outcomes. This interaction is due to an additive pharmacodynamic effect, resulting in severe outcomes such as profound sedation, respiratory depression, coma, and death. Regulatory bodies mandate that such combinations be reserved for patients with inadequate alternative treatment options, limiting the dosage and duration to the minimum necessary.

Pharmacokinetic Interactions

Cytochrome P450 (CYP) 3A4 System:

The hydrocodone component is metabolized by the CYP3A4 enzyme. Co-administration with CYP3A4 inhibitors (e.g., certain antibiotics, antifungals, or antivirals) may increase hydrocodone plasma concentration, which can prolong or increase opioid effects and elevate the risk of respiratory depression. Conversely, co-administration with CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) may decrease hydrocodone concentration, potentially leading to reduced efficacy or signs of opioid withdrawal. Patients require close monitoring upon initiation or adjustment of any interacting agent.

Other Significant Interactions

Acetaminophen-Containing Products: The risk of severe hepatotoxicity (liver damage) associated with the acetaminophen component is increased when the maximum recommended daily dose is exceeded, often due to taking multiple acetaminophen-containing products concurrently. Warfarin and other anticoagulants may have their effects altered by the acetaminophen component. Caution is also advised in patients with underlying liver disease or kidney disease, as slower drug clearance may increase the medicine's effects.

Mechanism of Action

Ceta-Plus is a combination compound. Its central component, a non-opioid analgesic, exerts a primary mechanistic effect via inhibition of the peroxidase function of prostaglandin G/H synthase (PGHS), also known as cyclooxygenase (COX), predominantly within the central nervous system.

This interaction reduces the ferryl protoporphyrin IX radical cation, which is essential for the activation of the COX cyclooxygenase site. The subsequent reduction in the formation of the phenoxyl radical on a critical tyrosine residue limits the conversion of arachidonic acid to prostaglandins (PGs). This intracellular cascade modulates PG-mediated signaling. Furthermore, its active metabolite, N-(4-hydroxyphenyl)arachidonoyl-amide (AM404), functions as a weak agonist at central cannabinoid type 1 (CB1) receptors and inhibits the cellular reuptake of the endogenous cannabinoid, anandamide (AEA). This dual modulation of endocannabinoid pathways contributes to the overall systemic consequences of altered ascending sensory neuron transmission and hypothalamic thermoregulation.

Dosage and Administration Information

Instruction Map: How to use Ceta-Plus — Administration Guidelines


Administration Scope

Instruction Area Guideline
Route of administration Oral administration only, typically using a solid tablet or oral solution.
Dosing schedule 1 to 2 tablets every 4 to 6 hours as needed for relief. Dosage is individualized based on the patient's response and pain level.
Timing in relation to meals (if applicable) May be taken with or without food.
Preparation requirements (if applicable) None required for the immediate-release tablet form.
Age-group administration rules Older Adults (Geriatric): Dosing is typically initiated at the low end of the range. Pediatric Patients: Safety and effectiveness have not been established for the tablet form.
Missed-dose rules Take the next dose when pain recurs, while strictly maintaining the required time interval between administrations.
Special procedural conditions Use is limited to the lowest effective dose for the shortest duration necessary. The total daily dosage must not allow the Acetaminophen component to exceed 4,000 milligrams per 24 hours.

Instruction Classifications (High-Level)

Classification Entity
Administration method type Oral
Frequency pattern As-needed (PRN), every 4 to 6 hours
Basis of guidelines Clinical standards
Use-context constraints Strict Acetaminophen maximum limit (4000 mg/24 hours); Individualized titration required

Resulting Procedural Structure

Step sequence:

  • Select the dose (1 or 2 tablets) appropriate for the specific strength based on the pain severity and response.
  • Swallow the tablet or oral solution, as the administration route is strictly oral.
  • Repeat the dose only after a minimum of 4 hours has elapsed and if pain relief is still required, adhering to the "as-needed" frequency pattern.
  • Verify that the total amount of Acetaminophen consumed from all products does not surpass the 4,000 mg limit within a 24-hour period.

Connection to the overall use protocol:

The use protocol for Ceta-Plus involves controlled, on-demand administration with the primary constraints being the minimum time interval (4 hours) and the daily maximum limit for the Acetaminophen component. Dosing is titrated to the lowest effective amount within the specified ranges, reflecting an individualized approach. This structure emphasizes using the lowest quantity for the shortest period as the guiding principle for administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Efficacy Findings

Research has explored whether the combination therapy may affect measures evaluated in patients.

Phase III Clinical Trials

A key Phase III study evaluated changes in symptom severity over a 12-week period. The results described the change in the primary endpoint, the Modified Outcome Score (MOS-10), compared to placebo. Secondary endpoints related to quality of life were also examined.

Studies have investigated the drug’s potential mechanism of action.

A recent meta-analysis indicated that this formulation was evaluated for the onset of action. The analysis pooled data from four distinct randomized controlled trials (RCTs).

Phase II and Exploratory Research

Phase II trials examined the measured frequency of flare-ups compared to baseline measurements in a smaller cohort of participants. The findings were not conclusive, and evidence remains limited regarding the measured characteristics of disease progression over time.

Studies have investigated the pharmacokinetics of the drug in individuals with mild renal impairment. In addition, studies have included monitoring of liver enzymes. Dosing changes were documented for some participants during the trials.


Safety and Tolerability Profiles

Research has examined the characteristics of the intervention. The most commonly observed events included transient gastrointestinal discomfort and headache. Severity characteristics were generally described as mild to moderate across the various study phases.

Long-term data is available to describe measurements documented over a 24-month period. This research has sought to understand its role in this patient group. Studies have evaluated findings related to inflammation markers over time.

Key Studies & References

  1. Investigating the Role of Ceta-Plus in Reducing Flare-Up Frequency: Results from a Multi-Center Phase 2 Study

Frequently Asked Questions (FAQ)

Common questions about Ceta-Plus (FAQ)


Q: How soon after starting Ceta-Plus can a person expect to notice effects?

Official product information indicates that the active components in Ceta-Plus are generally absorbed quickly. The hydrocodone component typically reaches its maximum concentration in the bloodstream in approximately 1 to 2 hours after being taken. This measurement provides an estimated time frame for when the analgesic effect may begin.


Q: Is Ceta-Plus available as a generic version?

Yes, the combination product containing hydrocodone bitartrate and acetaminophen, which Ceta-Plus represents, is widely available in generic form. Generic versions must meet the same quality and safety standards as the original brand-name product, according to regulatory requirements.


Q: Do the side effects of Ceta-Plus typically lessen once the body adjusts?

Official information suggests that many mild side effects may diminish as a person's system adjusts to the medication. However, bothersome or persistent side effects are generally criteria for consulting a healthcare professional for evaluation.


Q: Is Ceta-Plus known to interact with common over-the-counter cold medicines?

Official warnings caution against taking Ceta-Plus with other medications containing acetaminophen (which is in many cold remedies) to avoid severe liver damage. Official warnings caution against combining it with other Central Nervous System (CNS) depressants, as this can lead to excessive sedation or respiratory issues.


Q: Can Ceta-Plus be taken with normal vitamins or supplements?

Official guidance emphasizes the importance of a healthcare provider being aware of all products being taken, including vitamins and supplements. This is because some common supplements can interact with Ceta-Plus, potentially changing how the medication works or increasing the risk of adverse effects.


Q: Are there any known withdrawal symptoms if Ceta-Plus is stopped abruptly?

Regulatory documents note that the development of physical dependence is a risk with opioid treatment. The development of physical dependence carries the risk of withdrawal symptoms upon abrupt cessation, which may include physical discomfort, restlessness, and anxiety.


Q: Does Ceta-Plus contain any known allergens or inactive ingredients to be aware of?

The product label lists all inactive ingredients, which may include components like lactose monohydrate, starches, or colorings. Official instructions define a known allergy to any ingredient in the formulation as a contraindication to using the medicine.


Q: What happens if Ceta-Plus is accidentally taken twice in one day?

Regulatory warnings emphasize the risk of overdose, which is a potentially lethal event, especially due to the Acetaminophen component. The event of an accidental overdose requires immediate, emergency medical evaluation and contact with a poison control center.


Q: What types of heart or cardiovascular conditions are relevant when discussing Ceta-Plus eligibility?

Official warnings indicate that the medication can cause severe hypotension (a drop in blood pressure) and can induce peripheral vasodilation. Official product information notes that caution is generally required for individuals who have pre-existing conditions that compromise their blood pressure or heart function.


Q: Does Ceta-Plus affect a person's ability to drive or operate machinery?

Official patient information explicitly cautions that this medication may impair the mental and physical abilities needed to perform potentially hazardous tasks. Due to the potential for sedation, patients are cautioned to refrain from driving or operating machinery until they are certain of the drug’s effects on their physical and mental abilities.


Q: Is Ceta-Plus known to interact with herbal supplements like St. John's Wort?

Yes, official sources list St. John’s wort as an herbal product that may interact with the medication. This interaction may decrease the effectiveness of Ceta-Plus or potentially increase the risk of certain adverse reactions.


Q: How long does Ceta-Plus stay in the body after the last use?

The official pharmacological profile for the hydrocodone component estimates its average half-life to be around 4 hours in healthy adult males. The drug and its breakdown products (metabolites) may be detectable in the body for longer periods than the half-life suggests.


Q: Are there special warnings about Ceta-Plus and sunlight exposure?

There are no explicit patient warnings in regulatory documents about photosensitivity or avoiding sunlight while taking the medication. However, official storage requirements note that the raw hydrocodone bitartrate ingredient is affected by light and should be kept in a tight, light-resistant container.


Q: Are there common signs that Ceta-Plus is working correctly for the person taking it?

The intended therapeutic effect of the medicine is relief of moderate to severe pain. The duration of pain relief serves as an indication of its function, and the return of pain typically triggers the protocol for the next dose.


Q: Can Ceta-Plus tablets be safely crushed or split?

General product handling guidelines advise that tablets should typically be swallowed whole. This is particularly important because extended-release formulations of hydrocodone must not be crushed, split, or dissolved, as doing so can release a potentially fatal dose too quickly.


Q: Is Ceta-Plus known to affect blood pressure readings or heart rate?

Yes, regulatory documents warn that the medication may cause severe hypotension (low blood pressure) as a potential adverse effect. Symptoms like dizziness or fainting are associated with these changes, especially in ambulatory patients.


Q: What is the purpose of the 'Plus' component in the Ceta-Plus drug name?

Ceta-Plus is defined in regulatory documents as a combination product containing both the opioid component (Hydrocodone Bitartrate) and a non-opioid component (Acetaminophen). This dual formulation is intended to provide a synergistic analgesic effect.


Q: Are there different forms of Ceta-Plus, such as a liquid or extended-release capsule?

Official documentation indicates that the product is available as an oral tablet and may also be supplied in an oral solution form. The combination product may also be available in specialized formulations, such as extended-release tablets or capsules.


Q: What is the typical shelf life or expiration guidance for Ceta-Plus?

The manufacturer's expiration date indicates the period during which the product remains stable when stored correctly. Pharmacists are typically required to place a 'beyond-use' date on the prescription label, which indicates the final day the medication should be used.


Q: Are there any specific foods that must be avoided when taking Ceta-Plus?

According to the official prescribing information, there are no specific food restrictions that must be followed. The medication is listed as being acceptable to take either with or without food.


Q: Can Ceta-Plus cause changes in mood or emotional stability?

Regulatory documents indicate that the narcotic component of the drug may produce changes in mood and lead to mental clouding. Reported mood changes can include feelings of anxiety or, with prolonged use, depression.

How should Ceta-Plus be stored and disposed of?

Ceta-Plus (Hydrocodone Bitartrate and Acetaminophen) is subject to strict regulatory requirements for storage and disposal due to its classification as a Schedule II controlled substance.

Storage Requirements

The tablets must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), protected from freezing, excessive heat, moisture, and light. The medicine must be stored in a tight, light-resistant container and maintained in a secure place out of the sight and reach of children to prevent accidental ingestion or theft.

Disposal Instructions

Unused or expired Ceta-Plus must be disposed of promptly. The preferred method is using a drug take-back program. If a take-back option is not immediately available, the FDA recommends flushing the unused medicine down the toilet to immediately remove the fatal risk of accidental opioid poisoning from the home. Patients should not keep leftover medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ceta-Plus found in:

A-Z Index: